The red wine phenolics piceatannol and myricetin act as agonists for estrogen receptor α in human breast cancer cells

Journal of Molecular Endocrinology

Volumn 35, Issue 2, 2005, Pages 269-281

  Maggiolini, M ^a   Recchia, A G ^a   Bonofiglio, D ^a   Catalano, S ^a   Vivacqua, A ^a   Carpino, A ^a   Rago, V ^a   Rossi, R ^a   Andò, Sebastiano ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; MYRICETIN; PHENOL DERIVATIVE; PICEATANNOL; TRANSCRIPTION FACTOR GAL4;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER INCIDENCE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; ESTROGEN ACTIVITY; FEMALE; FOOD INTAKE; GENE ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNODETECTION; POSTMENOPAUSE; PRIORITY JOURNAL; RECEPTOR BINDING; RED WINE; STRUCTURE ANALYSIS;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FLAVONOIDS; GENE EXPRESSION REGULATION; GENES, REPORTER; HUMANS; MOLECULAR STRUCTURE; PHENOLS; PHYTOESTROGENS; PROTEIN-TYROSINE KINASES; RECOMBINANT FUSION PROTEINS; STILBENES; WINE;

EID: 27644594420     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.1.01783     Document Type: Article

References (79)

1. Ashby J, Tinwell H, Pennie W, Brooks AN, Lefevre PA, Beresford N & Sumpter JP 1999 Partial and weak oestrogenicity of the red wine constituent resveratrol: consideration of its superagonist activity in MCF-7 cells and its suggested cardiovascular protective effects. Journal of Applied Toxicology 19 39-45.
2. Aumais JP, Lee HS, Lin R & White JH 1997 Selective interaction of hsp90 with an estrogen receptor ligand-binding domain containing a point mutation. Journal of Biological Chemistry 272 12229-12235.
3. Azuma Y, Onishi Y, Sato Y & Kizaki H 1995 Effects of protein tyrosine kinase inhibitors with different modes of action on topoisomerase activity and death of IL-2-dependent CTLL-2 cells. Journal of Biochemistry 118 312-318.
4. Bagchi D, Das DK, Tosaki A, Bagchi M & Kothari SC 2001 Benefits of resveratrol in women's health. Drugs under Experimental and Clinical Research 27 233-248.
5. Basly JP, Marre-Fournier F, Le Bail JC, Habrioux G & Chulia AJ 2000 Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sciences 66 769-777.
6. Beato M, Truss M & Chavez S 1996 Control of transcription by steroid hormones. Annals of the New York Academy of Sciences 784 93-123.
7. Berry M, Nunez A-M & Chambon P 1989 Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. PNAS 86 1218-1222.
8. Bertelli AA, Giovannini L, Giannessi D, Migliori M, Bernini W, Fregoni M & Bertelli A 1995 Antiplatelet activity of synthetic and natural resveratrol in red wine. International Journal of Tissue Reactions 17 1-3.
9. Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC & Pezzuto JM 2001 Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Research 61 7456-7463.
10. Bianchini F & Vainio H 2003 Wine and resveratrol: mechanisms of cancer prevention? European Journal of Cancer Prevention 5 417-425.
11. Bowers JL, Tyulmenkov VV, Jernigan SC & Klinge CM 2000 Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141 3657-3667.
12. Brown AM, Jeltsch JM, Roberts M & Chambon P 1984 Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. PNAS 81 6344-6348.
13. Brownson DM, Azios NG, Fuqua BK, Dharmawardhane SF & Mabry TJ 2002 Flavonoid effects relevant to cancer. Journal of Nutrition 132 3482S-3489S.
14. Bunone G, Briand PA, Miksicek RJ & Picard D 1996 Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO Journal 15 2174-2183.
15. Burns J, Gardner PT, O'Neil J, Crawford S, Morecroft I, McPhail DB, Lister C, Matthews D, MacLean MR, Lean ME, Duthie GG & Crozier A 2000 Relationship among antioxidant activity, vasodilation capacity, and phenolic content of red wines. Journal of Agricultural and Food Chemistry 48 220-230.
16. Cantos E, Espin JC, Fernandez MJ, Oliva J & Tomas-Barberan FA 2003 Postharvest UV-C-irradiated grapes as a potential source for producing stilbene-enriched red wines. Journal of Agricultural and Food Chemistry 51 1208-1214.
17. Cavailles V, Augereau P & Rochefort H 1991 Cathepsin D gene of human MCF7 cells contains estrogen-responsive sequences in its 5′ proximal flanking region. Biochemical and Biophysical Research Communications 174 816-824.
18. Chang YC, Nair MG & Nitiss JL 1995 Metabolites of daidzein and genistein and their biological activities. Journal of Natural Products 58 1901-1905.
19. Ciocca DR & Fanelli MA 1997 Estrogen receptors and cell proliferation in breast cancer. Trends in Endocrinology and Metabolism 8 313-321.
20. Cosman F & Lindsay R 1999 Selective estrogen receptor modulators: clinical spectrum. Endocrine Reviews 20 418-434.
21. Cotton P 1994 Environmental estrogenic agents area of concern. JAMA 271 414-416.
22. Damianaki A, Bakogeorgou E, Kampa M, Notas G, Hatzoglou A, Panagiotou S, Gemetzi C, Kouroumalis E, Martin PM & Castanas E 2000 Potent inhibitory action of red wine polyphenols on human breast cancer cells. Journal of Cellular Biochemistry 78 429-441.
23. Early Breast Cancer Trialists Collaborative Group 1998 Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351 1451-1467.
24. Eisen A & Weber BL 1998 Recent advances in breast cancer biology. Current Opinion in Oncology 10 486-491.
25. Ekena K, Weis KE, Katzenellenbogen JA & Katzenellenbogen BS 1996 Identification of amino acids in the hormone binding domain of the human estrogen receptor important in estrogen binding. Journal of Biological Chemistry 271 20053-20059.
26. El Khissiin A & Leclercq G 1999 Implication of proteasome in estrogen receptor degradation. FEBS Letters 448 160-166.
27. Feigelson HS, Calle EE, Robertson AS, Wingo PA & Thun MJ 2001 Alcohol consumption increases the risk of fatal breast cancer (United States). Cancer Causes and Control 12 895-902.
28. Ferraroni M, Decarli A, Franceschi S & La Vecchia C 1998 Alcohol consumption and risk of breast cancer: a multicentre Italian case-control study. European Journal of Cancer 34 1403-1409.
29. Frankel EN, Waterhouse AL & Kinsella JE 1993 Inhibition of human LDL oxidation by resveratrol. Lancet 341 1103-1104.
30. Fuhrman B, Lavy A & Aviram M 1995 Consumption of red wine with meals reduces the susceptibility of human plasma and low-density lipoprotein to lipid peroxidation. American Journal of Clinical Nutrition 61 549-554.
31. Geahlen RL & McLaughlin JL 1989 Piceatannol (3,4,3′,5′-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor. Biochemical and Biophysical Research Communications 165 241-245.
32. Gehm BD, McAndrews JM, Chien PY & Jameson JL 1997 Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. PNAS 94 14138-14143.
33. Gehm BD, Levenson AS, Liu H, Lee EJ, Amundsen BM, Cushman M, Jordan VC & Jameson JL 2004 Estrogenic effects of resveratrol in breast cancer cells expressing mutant and wild-type estrogen receptors: role of AF1 and AF2. Journal of Steroid Biochemistry and Molecular Biology 88 223-234.
34. German JB & Walzem RL 2000 The health benefits of wine. Annual Review of Nutrition 20 561-593.
35. Goldberg DM, Hahn SE & Parkes JG 1995 Beyond alcohol: beverage consumption and cardiovascular mortality. Clinica Chimica Acta; International Journal of Clinical Chemistry 237 155-187.
36. Gronbaek M, Deis A, Sorensen TIA, Becker U, Schnohr P & Jensen G 1995 Mortality associated with moderate intakes of wine, beer or spirits. British Medical Journal 310 1165.
37. Gronbaek M, Becker U, Johansen D, Gottschau A, Schnohr P, Hein HO, Jensen G & Sorensen TI 2000 Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. Annals of Internal Medicine 133 411-419.
38. Hoskins K & Weber BL 1994 The biology of breast cancer. Current Opinion in Oncology 6 554-559.
39. Hsieh CY, Santell RC, Haslam SZ & Helferich WG 1998 Estrogenic effects of genistein on the growth of estrogen receptor-positive human breast cancer (MCF-7) cells in vitro and in vivo. Cancer Research 58 3833-3838.
40. Ikeda K, Orimo A, Higashi Y, Muramatsu M & Inoue S 2000 Efp as a primary estrogen-responsive gene in human breast cancer. FEBS Letters 472 9-13.
41. Jordan VC, Schafer JM, Levenson AS, Liu H, Pease KM, Simons LA & Zapf JW 2001 Molecular classification of estrogens. Cancer Research 61 6619-6623.
42. Katzenellenbogen BS, Choi I, Delage-Mourroux R, Ediger TR, Martini PG, Montano M, Sun J, Weis K & Katzenellenbogen JA 2000 Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology. Journal of Steroid Biochemistry and Molecular Biology 74 279-285.
43. Kopp P 1998 Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? European Journal of Endocrinology 138 619-620.
44. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S & Gustafsson JA 1997 Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptor alpha and beta. Endocrinology 138 863-870.
45. Laborda J 1991 36B4 cDNA used as an estradiol-independent mRNA control is the cDNA for human acidic ribosomal phosphoprotein PO. Nucleic Acids Research 19 3998.
46. Larrosa M, Tomas-Barberan FA & Espin JC 2004 The grape and wine polyphenol piceatannol is a potent inducer of apoptosis in human SK-Mel-28 melanoma cells. European Journal of Nutrition 43 275-284.
47. Levenson AS, Gehm BD, Pearce ST, Horiguchi J, Simons LA, Ward LE III, Jameson JL & Jordan VC 2003 Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ERα. International Journal of Cancer 104 587-596.
48. Lopez-Otin C & Diamandis EP 1998 Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocrine Reviews 19 365-396.
49. Lu R & Serrero G 1999 Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. Journal of Cellular Physiology 179 297-304.
50. McDonald MS, Hughes M, Burns J, Lean ME, Matthews D & Crozier A 1998 Survey of the free and conjugated myricetin and quercetin content of red wines of different geographical origins. Journal of Agricultural and Food Chemistry 46 368-375.
51. Maggiolini M, Donzé O & Picard D 1999 A non-radioactive method for inexpensive quantitative RT-PCR. Biological Chemistry 380 695-697.
52. Maggiolini M, Bonofiglio D, Marsico S, Panno ML, Cenni B, Picard D & Andò S 2001 Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells. Molecular Pharmacololgy 60 595-602.
53. Maggiolini M, Vivacqua A, Fasanella G, Recchia AG, Sisci D, Pezzi V, Montanaro D, Musti AM, Picard D & Andò S 2004 The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17 beta-estradiol and phytoestrogens in breast cancer cells. Journal of Biological Chemistry 279 27008-27016.
54. Markovits J, Linassier C, Fosse P, Couprie J, Pierre J, Jacquemin-Sablon A, Saucier JM, Le Pecq JB & Larsen AK 1989 Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II. Cancer Research 49 5111-5117.
55. Mgbonyebi OP, Russo J & Russo IH 1998 Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. International Journal of Oncology 12 865-869.
56. Nakagawa H, Kiyozuka Y, Uemura Y, Senzaki H, Shikata N, Hioki K & Tsubura A 2001 Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator. Journal of Cancer Research and Clinical Oncology 127 258-264.
57. Nawaz Z, Lonard DM, Dennis AP, Smith CL & O'Malley BW 1999 Proteosome-dependent degradation of the human estrogen receptor. PNAS 96 1858-1862.
58. Nonclercq D, Journe F, Body JJ, Leclercq G & Laurent G 2004 Ligand-independent and agonist-mediated degradation of estrogen receptor-alpha in breast carcinoma cells: evidence for distinct degradative pathways. Molecular and Cellular Endocrinology 227 53-65.
59. Pace-Asciak CR, Hahn S, Diamandis EP, Soleas G & Goldberg DM 1995 The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease. Clinica Chimica Acta; International Journal of Clinical Chemistry 235 207-211.
60. Pervaiz S 2003 Resveratrol: from grapevines to mammalian biology. FASEB Journal 14 1975-1985.
61. Piver B, Fer M, Vitrac X, Merillon JM, Dreano Y, Berthou F & Lucas D 2004 Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes. Biochemical Pharmacology 68 773-782.
62. Poschl G & Seitz HK 2004 Alcohol and cancer. Alcohol and Alcoholism 39 155-165.
63. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, Ruparelia KC, Lamb JH, Farmer PB, Stanley LA & Burke MD 2002 The cancer preventive agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. British Journal of Cancer 86 774-778.
64. Pratt WB & Toft DO 1997 Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocrine Reviews 18 306-360.
65. Safe S 2001 Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitamins and Hormones 62 231-252.
66. Safe SH 1995 Environmental and dietary estrogens and human health: is there a problem? Environmental Health Perspectives 103 346-351
67. Santagati S, Gianazza E, Agrati P, Vegeto E, Patrone C, Pollio G & Maggi A 1997 Oligonucleotide squelching reveals the mechanism of estrogen receptor autologous down-regulation. Molecular Endocrinology 7 938-949.
68. Seipel K, Georgiev O & Shaffner W 1992 Different activation domains stimulate transcription from remote (enhancer) and proximal (promoter) positions. EMBO Journal 11 4961-4968.
69. Simoncini T, Mannella P, Fornari L, Caruso A, Varone G & Genazzani AR 2004 Genomic and non-genomic effects of estrogens on endothelial cells. Steroids 69 537-542.
70. Stampfer MJ, Colditz GA, Willets WC, Speizer FE & Hennekens CH 1988 A prospective study of moderate alcohol consumption and the risk of coronary heart disease and stroke in women. New England Journal of Medicine 319 267.
71. Teugo PW, Fauconneau B, Deffieux G, Huguet F, Vercauteren J & Merillon JM 1998 Isolation, identification, and antioxidant activity of three stilbene glucosides newly extracted from Vitis vinifera cell cultures. Journal of Natural Products 61 655-657.
72. Truss M & Beato M 1993 Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocrine Reviews 14 459-479.
73. Tsai MJ & O'Malley B 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annual Review of Biochemistry 63 451-486.
74. van den Brandt PA, Goldbohm RA & van't Veer P 1995 Alcohol and breast cancer: results from The Netherlands Cohort Study. American Journal of Epidemiology 141 907-915.
75. Vuorinen H, Maatta K & Torronen R 2000 Content of the flavonols myricetin, quercetin, and kaempferol in finnish berry wines. Journal of Agricultural and Food Chemistry 48 2675-2680.
76. Webb P, Nguyen P, Shinsako J, Anderson C, Feng W, Nguyen MP, Chen D, Huang SM, Subramanian S, McKinerney E, Katzenellenbogen BS, Stallcup MR & Kushner PJ 1998 Estrogen receptor activation function 1 works by binding p160 coactivator proteins. Molecular Endocrinology 12 1605-1618.
77. Whitehead TP, Robinson D, Allaway S, Syms J & Hale A 1995 Effect of red wine ingestion on the antioxidant capacity of serum. Clinical Chemistry 41 32-35.
78. Wieder T, Prokop A, Bagci B, Essmann F, Bernicke D, Shulze-Osthoff K, Dorken B, Schmalz HG, Daniela PT & Henze G 2001 Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary leukemic lymphoblasts. Leukemia 15 1735-1742.
79. Wolter F, Clausnitzer A, Akoglu B & Stein J 2002 Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cell lines. Journal of Nutrition 132 298-302.